Literature DB >> 21878671

Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.

David A Jacobsohn1, Mukta Arora, John P Klein, Anna Hassebroek, Mary E Flowers, Corey S Cutler, Alvaro Urbano-Ispizua, Brian J Bolwell, Joseph H Antin, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S Cairo, Roger H Herzig, Luis M Isola, Thomas R Klumpp, Stephanie J Lee, Effie W Petersdorf, Stella Santarone, Robert P Gale, Harry C Schouten, Stephen R Spellman, Daniel J Weisdorf, John R Wingard, Mary M Horowitz, Steven Z Pavletic.   

Abstract

There is a paucity of information regarding the factors that affect nonrelapse mortality (NRM) and overall survival among children that develop chronic graft-versus-host disease (cGVHD). We performed multivariate analyses using data from the Center for International Blood and Marrow Transplant Research to identify risk factors for NRM and survival in 1117 pediatric subjects with leukemia or myelodysplastic syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between 1995 and 2004. We identified 4 variables associated with higher NRM: HLA partially matched or mismatched URD, peripheral blood cell graft, Karnofsky/Lansky score < 80 at cGVHD diagnosis, and platelets < 100 × 10(9)/L at cGVHD diagnosis. Factors associated with significantly worse survival were: age > 10 years, transplantation from HLA partially matched or mismatched URD, advanced disease at transplantation, Karnofsky/Lansky < 80; and platelets < 100 × 10(9)/L. Cumulative incidence of discontinuation of systemic immune suppression at 1, 3, and 5 years after diagnosis of cGVHD were 22% (20%-25%), 34% (31%-37%), and 37% (34%-40%), respectively. This is the largest study elucidating variables affecting outcome after diagnosis of cGVHD in pediatric allograft recipients. These variables may be useful for risk stratification, development of future clinical trials, and family counseling in children with cGVHD.

Entities:  

Mesh:

Year:  2011        PMID: 21878671      PMCID: PMC3204914          DOI: 10.1182/blood-2011-04-349068

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

Authors:  Gorgun Akpek; Stephanie J Lee; Mary E Flowers; Steven Z Pavletic; Mukta Arora; Shing Lee; Steven Piantadosi; Katherine A Guthrie; James C Lynch; Alessandra Takatu; Mary M Horowitz; Joseph H Antin; Daniel J Weisdorf; Paul J Martin; Georgia B Vogelsang
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

2.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Authors:  K M Sullivan; R P Witherspoon; R Storb; P Weiden; N Flournoy; S Dahlberg; H J Deeg; J E Sanders; K C Doney; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

3.  Chronic graft-versus-host disease: a prospective cohort study.

Authors:  Mukta Arora; Linda J Burns; Stella M Davies; Margaret L Macmillan; Todd E Defor; Wesley J Miller; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-01       Impact factor: 5.742

4.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

5.  Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.

Authors:  Marco Zecca; Arcangelo Prete; Roberto Rondelli; Edoardo Lanino; Adriana Balduzzi; Chiara Messina; Franca Fagioli; Fulvio Porta; Claudio Favre; Andrea Pession; Franco Locatelli
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.

Authors:  Mary E D Flowers; Pablo M Parker; Laura J Johnston; Alice V B Matos; Barry Storer; William I Bensinger; Rainer Storb; Frederick R Appelbaum; Stephen J Forman; Karl G Blume; Paul J Martin
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Graft-v-host disease is associated with autoimmune-like thrombocytopenia.

Authors:  C Anasetti; W Rybka; K M Sullivan; M Banaji; S J Slichter
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

9.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

Authors:  N A Kernan; G Bartsch; R C Ash; P G Beatty; R Champlin; A Filipovich; J Gajewski; J A Hansen; J Henslee-Downey; J McCullough
Journal:  N Engl J Med       Date:  1993-03-04       Impact factor: 91.245

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  26 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

2.  Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease.

Authors:  Masahiro Hirayama; Eiichi Azuma; Atsuko Nakagawa-Nakazawa; Tadashi Kumamoto; Shotaro Iwamoto; Keishiro Amano; Shigehisa Tamaki; Eiji Usui; Yoshihiro Komada
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 3.  Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts.

Authors:  M Aljurf; J D Rizzo; M Mohty; F Hussain; A Madrigal; M C Pasquini; J Passweg; N Chaudhri; A Ghavamzadeh; H E Solh; Y Atsuta; J Szer; Y Kodera; D Niederweiser; A Gratwohl; M M Horowitz
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 4.  Evolving concepts in prognostic scoring of chronic GvHD.

Authors:  A Lazaryan; M Arora
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.483

5.  Update of humanized animal disease models in studying Graft-versus-host disease.

Authors:  Feng Huang; Feng Lin Cao; Song Guo Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

6.  How I treat childhood CML.

Authors:  Jeffrey R Andolina; Steven M Neudorf; Seth J Corey
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

Review 7.  Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Ema Prenc; Drazen Pulanic; Maja Pucic-Bakovic; Marija Pezer; Lana Desnica; Radovan Vrhovac; Damir Nemet; Steven Z Pavletic
Journal:  Biochim Biophys Acta       Date:  2016-02-26

8.  Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.

Authors:  Mukta Arora; Michael T Hemmer; Kwang Woo Ahn; John P Klein; Corey S Cutler; Alvaro Urbano-Ispizua; Daniel R Couriel; Amin M Alousi; Robert Peter Gale; Yoshihiro Inamoto; Daniel J Weisdorf; Peigang Li; Joseph H Antin; Brian J Bolwell; Michael Boyiadzis; Jean-Yves Cahn; Mitchell S Cairo; Luis M Isola; David A Jacobsohn; Madan Jagasia; Thomas R Klumpp; Effie W Petersdorf; Stella Santarone; Harry C Schouten; John R Wingard; Stephen R Spellman; Steven Z Pavletic; Stephanie J Lee; Mary M Horowitz; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

9.  Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study.

Authors:  Lori Wiener; Kristin Baird; Caroline Crum; Kimberly Powers; Paul Carpenter; K Scott Baker; Margaret L MacMillan; Eneida Nemecek; Jin-Shei Lai; Sandra A Mitchell; David A Jacobsohn
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

10.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.